An Open Label, Non-Comparative, Phase II Study of ZD1839 (Iressa) as First-Line Treatment in Subjects With Relapsed Prostate Cancer Following Radical Prostatectomy or Radiotherapy
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006902/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
To evaluate activity of gefitinib in subjects with relapsed prostate cancer by estimating PSA
response rate at study closure
提供机构：
Vivli
创建时间：
2021-04-16
